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The Mental Health Centers for Intervention Development
and Applied Research (CIDAR) program prioritized research
to provide an evidence base for biomarker development. At
the Zucker Hillside Hospital (ZHH), our CIDAR grant supported research on a comprehensive investigation of treatment
response and outcome in first episode schizophrenia. Results
provide evidence that baseline neuroimaging, neurocognitive,
and genetic measures are significantly associated with clinical response to treatment, and that our currently available
interventions can effectively treat aspects of psychotic illness,
as well as potentially reduce comorbidity associated with illness. Future research may include combining modalities to
more robustly predict response and identify treatment targets, as well as to further develop more effective intervention
strategies for these devastating and disabling disorders.
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In many areas of medicine, heterogeneity of patient outcomes is managed by the availability of multiple therapeutic options, and treatment decisions are guided by
clinical biomarkers. Well-known examples in broad
clinical use include the HER2 marker for herceptin treatment of breast cancer,1 and natriuretic peptide levels for
diagnosis and prognosis of heart failure.2 By contrast,
treatment options for patients with schizophrenia are
relatively undifferentiated, and clinicians lack objective tools to dissect patient heterogeneity with respect to
treatment and prognosis. Development of biomarkers in
psychiatry can be critical to both the application of existing treatments and the development of novel treatments.
The announcement of the Mental Health Centers
for Intervention Development and Applied Research
(CIDAR) program in 2005 prioritized research to provide an evidence base for biomarker development. This

announcement coincided with an important evolution in
research at our institution, the Zucker Hillside Hospital
(ZHH). Developments in neuroimaging, neurocognition,
and molecular genetics provided the means to broaden
our treatment research in first episode schizophrenia to
encompass the development of individualized assessment
tools to dissect the heterogeneity of treatment response
in this important population. The CIDAR program provided the first NIH-funded mechanism to integrate these
efforts into a comprehensive investigation of treatment
response and outcome in first episode schizophrenia.
This theme is focused on the first episode of psychosis,
which may be the most critical period in the life of an individual with schizophrenia, and remains the most opportune time for the study of key mechanisms that influence
treatment response and outcome of this often chronically
disabling disorder. Several factors render the first episode
a critical research window: first episode patients are generally young, and therefore within a relatively restricted age
range; they have a shorter duration of psychotic symptoms;
and less illness-related functional and social impairment
related to chronicity of illness. Perhaps most critical is that
first episode patients have minimal prior psychopharmacological treatment, reducing medication confounds for
research aimed at identifying the neurobiological substrates
associated with illness and the prediction of illness course.
The ZHH CIDAR (P50MH080173; Dissecting the
heterogeneity of treatment response in first episode schizophrenia; PI: Anil K. Malhotra), funded in 2008, integrated therapeutic knowledge and experience with the
expertise of investigators utilizing neurocognitive, neuroimaging and molecular genetics approaches to biomarkers development. We focused on the assessment of
a cohort of first episode schizophrenia patients participating in a 12-week clinical trial of 2 second generation
antipsychotics (SGAs), aripiprazole and risperidone, and
a follow-up extension phase of controlled treatment for
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1 year. The primary CIDAR assessments were conducted
prior to the initiation of treatment and during 12 weeks
of double-blind treatment. The CIDAR comprises 3
cores supporting 3 independent projects, with additional
NIH and FDA funding to support a supplemental project focused on the reactions of young people with early
phase schizophrenia to tobacco smoking warning materials. The major aim of each of the 3 initial projects was to
identify predictors of SGA response in this cohort, using
neuroimaging, neurocognitive and genetic indices.
Progress to Date
At the conclusion of CIDAR patient recruitment in 2014,
198 first episode schizophrenia patients had entered the
parent clinical trial, with a majority of them contributing
additional data to the other projects within the CIDAR.
Initial results include structural neuroimaging studies suggesting that observed antipsychotic-drug induced changes
in fractional anisotropy, a putative measure of white matter
integrity, may be related to changes in circulating lipid levels,3 assessments of the relationship of cognitive function to
brain connectivity,4 and molecular genetics work identifying the melanocortin 4 receptor (MC4R) locus as a strong
predictor of antipsychotic drug-induced weight gain.5
The CIDAR has been most successful in the adoption
of resting state MRI (rs-fMRI) to identify biomarkers of
antipsychotic drug response We have recently published a
pair of studies demonstrating 2 facets of our approach to
biomarker development in the context of CIDAR antipsychotic drug treatment: (1) identification of baseline
predictors of treatment response and (2) identification of
longitudinal indicators of target engagement.6,7
As an example of prognostic biomarker development, we
utilized seed-based rs-fMRI analysis to examine the relationship between baseline (pretreatment) functional connectivity
and subsequent response to SGA treatment. A striatal connectivity index (SCI) was established as a predictor of treatment response and replicated in a second sample.6 Sensitivity
and specificity in the replication sample suggests potential
clinical application. Post-treatment rs-fMRI scans identified a different set of striatal connections that changed as a
function of successful treatment.7 These data are consistent
with an independent study8 in which symptom improvement
with antipsychotic treatment was associated with changes in
fronto-striatal connectivity. These fronto-striatal networks
may serve as a measure of target engagement in the development of novel therapeutic agents.
In This Issue
In this theme issue of Schizophrenia Bulletin, we highlight results of the pivotal clinical trial at the heart of the
CIDAR, as well as our most recent findings of prognostic relevance. Robinson and colleagues (this issue) present
data from the first large scale double-masked first-episode

randomized comparison of aripiprazole and risperidone.
One hundred ninety-eight schizophrenia-spectrum participants (ages 15–40) were randomly assigned and followed
for 12 weeks. Of note, positive symptom response rates did
not significantly differ (62.8% vs 56.8%) between treatment
groups nor was there a significant difference in the mean
time to achieve clinical response. While positive symptom
treatment efficacy was similar, there was substantial difference in side effect profiles. Patients treated with aripiprazole
experienced greater akathisia during the trial, although differences were nonsignificant by the end of trial. By contrast,
risperidone-treated patients had greater increases in total
and LDL cholesterol, fasting glucose and prolactin levels.
Taken together, the data suggest that while both drugs are
effective in first episode patients, the metabolic advantages
of aripiprazole may suggest it as a preferred choice over
risperidone for young patients in whom treatment may be
indicated for an extended period of time.
The second major aim of the CIDAR: to identify
pretreatment neurocognitive indices that may be indicators of treatment response is addressed by Trampush
and colleagues (this issue). Twelve weeks of treatment
with aripiprazole and risperidone had minimal effects
on cognitive function, as assessed with the MATRICS
Consensus Cognitive Battery (MCCB). Although performance on indices of general cognitive function, working memory, and verbal learning improved over time,
change was mediated by improvements in both positive
and negative symptoms, reflecting “pseudospecificity” or
practice effect.9 These data are consistent with prior work
from our group in first episode patients,10 as well as studies in more chronic patients in which minimal effects of
SGA treatment were found on neurocognitive function.11
Intriguingly, however, at baseline, a measure of planning
and reasoning significantly predicted whether positive
symptom remission was achieved during the 12-week
trial. These data suggest that a simple paper and pencil
test may serve as a potentially useful predictive biomarker
of antipsychotic drug response.
The third paper addresses genetic predictors of antipsychotic drug response. Previously, we have found that
a polymorphism in the promoter region of the DRD2
gene significantly influenced antipsychotic drug efficacy
in first episode patients,12 as well as in more chronically
ill patients.13 Moreover, the PGC consortium reported
that a locus near the DRD2 gene attained genome-wide
significance for association to schizophrenia,14 providing
the first robust evidence that genetic variation in the dopamine system may influence illness susceptibility. Therefore,
Zhang and colleagues (this issue) assessed the relationship
of this new DRD2 locus to treatment response and found
evidence that variation at this risk locus was associated
with positive symptom treatment response.
The final paper addresses whether tobacco warning
materials designed to reduce cigarette smoking in the
general population is effective in young patients with
1225
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schizophrenia. Schizophrenia is associated with intense
smoking and related morbitiy and mortality. However,
warning materials have not been specifically designed for
use in this population. Coletti and colleagues (this issue)
examined whether picture and video materials depicting the dangers of smoking, many of which can be quite
graphic and potentially disturbing, would be acceptable
to young patients with psychosis. Their data suggest that
the materials were well-received with some evidence of a
decline in smoking rates
Taken together, these papers as well as in our previous rs-fMRI publications, suggest that identification of
biomarkers of antipsychotic drug response is feasible in
first episode patient populations and that our currently
available interventions can effectively treat aspects of
psychotic illness, as well as potentially reduce comorbidity associated with illness. As our CIDAR-supported
work found evidence that baseline neuroimaging, neurocognitive, and genetic measures are significantly associated with clinical response to treatment, the next steps
will include combining modalities to more robustly predict response and identify treatment targets, as well as to
further develop more effective intervention strategies that
help ameliorate the suffering of patients with these devastating and disabling disorders.
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